Chris is an Analyst at ShangBay Capital where he is responsible for supporting portfolio companies, deal sourcing, due diligence, and operations.

 

Previously, he was a lab researcher at the Stanford Cancer Institute’s Mackall Lab where he conducted research within the field of immunotherapy. He also has experience in medical device engineering, vaccine development, and immunology through his time at Duke Empirical, the clinical and translational research center at the University of Buffalo, and within Stanford’s Department of Medicine.

 

Chris holds a B.S. and B.A. in Biology and Creative Writing from Canisius College and a M.Sc in Animal Science from Stanford University.